Policy moves fast. You shouldn’t have to chase it.
Built by a former cannabis regulator, Policy, Decoded is your high-signal daily briefing for operators, investors, and policymakers navigating the collision of law, regulation, and business.
The cannabis policy landscape consolidated power this week as DEA Administrator Terry Cole gained unprecedented control over rescheduling while enforcement actions across multiple states revealed the regulatory tensions defining this transitional moment. From Arizona's nepotism scandals in testing labs to federal labor rulings against major MSOs, the industry faces mounting pressure to professionalize operations while navigating an increasingly complex compliance environment. With the Supreme Court preparing to weigh gun rights for cannabis users and Congress targeting illegal operations with Chinese connections, federal and state authorities are drawing clearer lines between legitimate operators and bad actors.
📊 Read the intelligence
🔫 Track the enforcement
🧠 Decode the implications
Your trusted guide through the policy maze others can't decode. Have a great weekend - we'll see you Monday.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: The Supreme Court will privately discuss whether to review U.S. v. Cooper in a September 29 conference, a case challenging the federal ban on gun ownership by marijuana users under Section 922(g)(3). Multiple federal appeals courts have recently questioned the constitutionality of the blanket prohibition, with the Fifth Circuit ruling it unconstitutional as applied to occasional users and the Third Circuit requiring "individualized judgments" rather than categorical bans (Marijuana Moment). The Justice Department is simultaneously pushing the Court to review U.S. v. Hemani, where Solicitor General D. John Sauer argues cannabis users pose "a clear danger of misusing firearms," while strategically selecting a defendant who used both cocaine and cannabis to strengthen their case.
💡 Why It Matters: This represents the most significant constitutional challenge to federal cannabis prohibition since legalization began, potentially affecting millions of state-legal users across 38+ jurisdictions. The circuit split on 922(g)(3) has created a "confusing regulatory landscape" that even the NRA acknowledges undermines Second Amendment rights. Kentucky recently warned medical marijuana patients they'd be federally prohibited from gun ownership, while Pennsylvania and Colorado have introduced competing legislation. The convergence with ongoing rescheduling discussions, hemp regulation battles in the Farm Bill, and other federal cannabis policy debates puts the plant squarely on Washington's agenda across multiple constitutional and regulatory fronts.
🧠 THC Group Take: The government's strategic forum shopping in Hemani is a pretty strategic litigation move. Choosing a defendant with a cocaine charge over sympathetic medical patients shows DOJ understands the optics battle ahead. From a regulatory standpoint, the individualized assessment approach emerging from circuit courts mirrors how we handled other constitutional challenges during my time in regulation: blanket prohibitions rarely survive strict scrutiny when fundamental rights collide. The real regulatory nightmare isn't the legal uncertainty, but the enforcement reality. State regulators are caught between federal law requiring gun prohibition disclosures on cannabis applications and state constitutional provisions protecting both rights. Whether SCOTUS upholds broad federal authority or requires individualized assessments, expect states to push back through legislation protecting both rights, creating the kind of federal-state enforcement conflicts that make regulatory compliance nearly impossible for businesses operating in both spaces. This one is worth keeping an eye on.
Fast-moving headlines, flagged for what matters.
Arizona's Department of Health Services quietly fined Full Spectrum Lab $120,000 for nepotism violations after discovering the lab's technical director is the son of Downtown Dispensary's chief financial officer, the lab's biggest client (Arizona Republic). The Tucson facility also failed quality-control testing and couldn't ensure "scientifically defensible" analytical data for contaminants and potency during May inspections. The case reveals a web of family relationships where Sam Levenberg formed the lab while serving as Downtown Dispensary's CFO, his wife runs the lab as president, his son serves as technical director, and his daughter works in dispensary product development. Of Arizona's 11 certified labs, six have faced enforcement referrals in three years, yet the state obscures enforcement information and hasn't released fine records since 2023. Industry insiders report "large-scale corruption" where labs skew results to retain dispensary clients who can "shop" for favorable testing outcomes, undermining consumer safety and market integrity.
A bipartisan coalition of 32 attorneys general, including Arizona's Kris Mayes and Michigan's Dana Nessel, urged Congress to pass the SAFER Banking Act of 2025, which would allow banks to serve state-regulated cannabis businesses without federal penalties (Arizona Attorney General, Michigan Attorney General). The coalition argues that forcing legal cannabis operators to handle $30.1 billion in annual sales through cash-only transactions creates public safety risks and undermines tax collection efforts. Currently, 39 states permit medical cannabis while 24 allow adult use, yet many state agencies report being turned away by financial institutions when trying to deposit cannabis-related tax payments. The attorneys general emphasize the legislation wouldn't change cannabis's federal legal status or encourage legalization in prohibition states, but would create targeted banking safe harbors for compliant state-licensed operators. The coordinated push comes as legal cannabis sales are projected to reach $34 billion by end of 2025, supporting approximately 425,000 jobs nationwide while generating significant state tax revenues that remain difficult to process through traditional banking channels.
Texas hemp industry advocates are mobilizing fierce opposition to Senate Bill 5, which would ban products containing "any detectable amount" of cannabinoids beyond CBD and CBG during the state's ongoing special session (Law360). The legislation, championed by Lt. Gov. Dan Patrick and Sen. Charles Perry, represents a revival of earlier efforts after Gov. Abbott vetoed a similar ban in June, preferring regulation over prohibition. Hemp industry leaders argue the blanket ban would eliminate 50,000 jobs and billions in tax revenue while pushing consumers to unregulated black markets. The Texas Hemp Business Council remains "cautiously optimistic" that House lawmakers will favor their preferred regulatory approach over the Senate's prohibition strategy. Abbott's position appears nuanced, supporting age restrictions and synthetic product bans while maintaining the hemp industry's agricultural foundation. The political calculus hinges on whether House pragmatism can overcome Senate prohibition fervor before the 30-day session expires. Everything is bigger in Texas, including the drama.
Oregon officials issued a draft ballot title for a 2026 initiative to legalize cannabis social lounges, bringing organizers closer to launching signature collection efforts (Marijuana Moment). The Oregon Cannabis Cafe Coalition must gather over 117,000 valid signatures by November 2026 after successfully submitting 1,400 verified signatures to secure the ballot title. The proposed measure would allow microbusiness-operated lounges where adults 21+ could consume cannabis they bring themselves, with no on-site sales permitted but allowing food and beverage sales. Alcohol and tobacco would be prohibited, lounges must close by 2AM, and local governments could regulate numbers and impose additional restrictions. The initiative reflects growing momentum for public consumption spaces as legal markets mature, addressing the gap between home-only consumption laws and social cannabis use that many consumers seek in regulated environments.
NYC Mayor Eric Adams suggested marijuana smoking should be "relegated to certain areas" rather than throughout city streets, citing widespread odor complaints as a quality-of-life issue (Fox 5 NY). Speaking on The New York Post's podcast, Adams criticized the state legislature for not imposing location restrictions when legalizing cannabis in 2021, calling it "one of the negative impacts of our cannabis law." Under current New York law, marijuana can be smoked anywhere tobacco is permitted, excluding vehicles, restaurants, federal property, and most public parks. New Yorkers remain divided, with some parents expressing concern about children's exposure while others dismiss the smell as minor compared to typical city odors. The comments highlight implementation tensions between legalization's personal freedom promise and practical challenges in dense urban environments where public consumption inevitably affects non-users.
A National Labor Relations Board judge ordered Curaleaf's Phoenix Midtown dispensary to rehire budtender Nickolas Fredrickson with back pay after finding the company violated federal labor law by firing him for union activities (Phoenix New Times). Fredrickson was terminated April 21, 2024, one day after participating in a United Food and Commercial Workers Local 99 picket outside another Curaleaf location, with Judge Mara-Louise Anzalone ruling the company "manufactured" attendance infractions as part of a plan to eliminate their "chief union adherent." The ruling exposes the intensifying labor relations tensions as cannabis MSOs resist unionization while workers leverage federal protections unavailable to most industries. Arizona reflects broader national dynamics where workers at two Zen Leaf dispensaries ratified the state's first cannabis union contract in June 2024, while seven other facilities including multiple Curaleaf locations have voted to unionize despite company opposition. Curaleaf declined to comment on whether it will appeal the ruling, as cannabis workers nationwide increasingly challenge MSO resistance to collective bargaining through NLRB enforcement, creating a new front in the industry's regulatory battles.
The House Appropriations Committee directed federal agencies to "eliminate" illegal marijuana grows on public lands and investigate money laundering by Chinese Communist Party-connected cannabis businesses through new spending bill language (Marijuana Moment). The Interior appropriations report requires Forest Service and Bureau of Land Management coordination with Justice and Homeland Security departments to eradicate unsanctioned operations while developing cost estimates for environmental reclamation within 180 days. Separately, the Commerce-Justice-Science bill mandates DOJ utilize anti-money laundering programs to investigate CCP-linked marijuana businesses and their financial service providers, with a 120-day reporting requirement. The measures reflect growing congressional focus on illegal operations that bypass state regulatory frameworks and environmental protection on federal lands. The directives come as the same appropriations process includes controversial provisions to block marijuana rescheduling, highlighting how cannabis enforcement remains caught between legitimate market protection and broader national security concerns around illicit operations.
Compass Ventures, a Curaleaf subsidiary, filed suit against the Illinois Department of Agriculture for denying permits to expand its Montgomery County cultivation center with a 42,000-square-foot "hoop house" structure (Law360). The lawsuit alleges regulatory inconsistency, claiming the agency previously approved similar greenhouse-style expansions for at least two competing operators while blocking Curaleaf's identical request. Compass Ventures operates a cultivation facility in Litchfield that Curaleaf acquired through its 2020 $830 million Grassroots acquisition, which brought the Massachusetts-based MSO nine Illinois dispensaries and cultivation assets. The legal challenge highlights ongoing tensions around regulatory discretion in state cannabis markets, where permitting decisions can significantly impact competitive positioning among major operators. Illinois regulators have broad authority over cultivation facility modifications, but equal treatment claims could force greater transparency in expansion approvals as the state's $1+ billion cannabis market continues consolidating around major MSOs.
NIST researchers made the first successful detection of THC in breath after participants consumed cannabis edibles, proving that swallowed cannabis eventually reaches the lungs and can be exhaled (NIST). The study tracked 29 participants over three hours after consuming edibles containing 5-100mg of THC, with 19 showing significant breath THC increases despite the digestive pathway. This breakthrough addresses a critical enforcement gap where nearly 20% of cannabis users admit to driving after consumption, yet law enforcement lacks reliable roadside testing beyond subjective field sobriety assessments. The research suggests multiple breath measurements over time could distinguish recent use from residual THC levels that persist for weeks in regular users. While the findings provide hope for future cannabis breathalyzer development, translating laboratory detection into roadside reality will require extensive validation, equipment standardization, and legal frameworks that can withstand courtroom challenges about timing, dosage, and actual impairment correlation.
Turkish parliament passed legislation allowing licensed pharmacies to sell cannabis-derived medical products, with cultivation oversight by the Agriculture Ministry and processing/sales regulation by the Health Ministry (Cannabis Law Report). The law restricts sales to low-THC products (under 0.3%) for medical conditions like cancer and multiple sclerosis, with electronic monitoring ensuring safety and traceability. Turkish Pharmacists' Association board member Taner Ercanlı noted the products are recommended for severe pain management due to their analgesic and antidepressant properties. The move aligns Turkey with global medical cannabis practices while maintaining strict pharmaceutical distribution controls, representing another significant step in international medical cannabis acceptance. Pharmacists welcomed the legislation as enhancing Turkey's competitiveness in the growing therapeutic cannabis sector while ensuring patient access through traditional healthcare channels.
The deeper pattern behind today’s moves — and why it matters next.
🧾 Context: As we covered this week, newly confirmed DEA Administrator Terrance Cole now holds unprecedented control over cannabis rescheduling after Judge John Mulrooney's August 1 retirement sent all decisions directly to his desk. This consolidates what was already the most pivotal federal cannabis appointment in decades into a single decision point that could reshape the entire industry.
🔎 What It Signals: Cole's immediate challenge isn't just procedural but deeply political. The retirement eliminates the hearing process we expected would drag into 2026, forcing Cole into an early defining moment. His confirmation testimony about making rescheduling a "first priority" while simultaneously expressing skepticism about the science creates inherent tension. The administrative consolidation suggests urgency from above, but Cole's anti-cannabis track record indicates potential resistance to being the architect of historic drug policy reform.
🧠 THC Group Take: This represents the regulatory equivalent of all roads leading to Rome. During my time overseeing complex regulatory processes, these moments of consolidated authority either accelerate outcomes dramatically or create bottlenecks that kill momentum entirely. Cole can't hide behind administrative procedure anymore - his next move reveals whether Trump's cannabis campaign rhetoric translates to policy action. The political math remains compelling: rescheduling delivers 280E relief that could save operators billions while providing Trump a fulfilled campaign promise during a period when he needs accessible wins. But the speed of Mulrooney's exit suggests someone wants this resolved quickly, not methodically reviewed. If Cole appoints a new judge and restarts proceedings, it signals this administration views cannabis reform as more politically risky than rewarding. The industry's cautious optimism reflects an understanding that Cole's personal views may matter less than administrative pressure to deliver results. Watch his first 90 days - they'll determine whether we're entering a new era of federal cannabis policy or witnessing the slow-motion death of rescheduling through bureaucratic resistance.
From the hearing room to the comment section — we’re watching it all.
🎤 Cypress Hill received the Golden Advocacy Award at the California State Fair's Cannabis Awards, celebrating three decades of unapologetic cannabis advocacy that helped normalize weed culture long before legalization. The hip-hop legends now channel their activism into business with B-Real's Dr. Greenthumb dispensaries across six California cities, while their We Legalized It tour donates $1 per ticket to Last Prisoner Project for those still incarcerated for the plant they helped destigmatize.
🧠 A single dose of psilocybin with talk therapy relieved depression in cancer patients for up to two years, with 53.6% of participants experiencing significant improvement according to new research in Cancer journal (High Times). The breakthrough offers hope for cancer care, where depression significantly increases mortality risk and complicates treatment outcomes.
💼 A majority of marijuana consumers say cannabis use has positively impacted their careers, with 54% reporting positive effects according to a new NuggMD poll, challenging prohibitionist narratives about workplace motivation (Marijuana Moment). Only 10% reported negative career impacts while 36% saw no effect.
